FDA calendar · April 2024 · built from SEC filings

PDUFA dates April 2024: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

2 PDUFA dates fell in April 2024: ANKTIVA (April 23), IBRX (April 23). The FDA calendar also recorded 53 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in April 2024

2 PDUFA target action dates in April 2024, soonest first, each linked to the SEC filing or FDA page that disclosed it. Data as of .
PDUFA dateCompanyTickerDrugIndicationSource
April 23, 2024ImmunityBio, Inc.IBRXANKTIVA (inbakicept)sec_424b, filed 2025-07-28
April 23, 2024ImmunityBio, Inc.IBRXNot namedsec_424b, filed 2025-07-28

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

April 2024: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
Apr 2024Month disclosed—ADPTAdvisory committee—PositiveSEC Form 10-K
Apr 2024Month disclosedSELARSDIALVOFDA approval—ApprovedSEC 8-K Exhibit 99.1
Apr 2024Month disclosedWEZLANA® (ustekinumab)ALVOFDA approval—ApprovedSEC 8-K Exhibit 99.1
Apr 2024Month disclosed—ALVOFDA approval—ApprovedSEC 8-K Exhibit 99.1
Apr 2024Month disclosedZUSDURI (mitomycin)URGNNDA/BLA acceptedrecurrent low-grade intermediate risk NMIBCCompletedSEC Form 10-Q
April 5, 2024Fasenra (benralizumab)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
April 5, 2024Dovato (dolutegravir sodium; lamivudine)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
April 5, 2024Libtayo (cemiplimab-rwlc)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
April 10, 2024Retevmo (selpercatinib)LLYFDA approval—ApprovedopenFDA Drugs@FDA
April 12, 2024Mytesi® (crofelemer)JAGXFDA approval—ApprovedSEC Form 10-Q
April 12, 2024Entresto (sacubitril; valsartan)NVSFDA approval—ApprovedopenFDA Drugs@FDA
April 12, 2024Entresto (sacubitril; valsartan)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
April 16, 2024—ABEOComplete Response Letterwith recessive dystrophic epidermolysis bullosaCRL issuedSEC Form 10-Q
April 16, 2024prademageneABEOComplete Response Letter—CRL issuedFDA Complete Response Letters
April 16, 2024Selarsdi (ustekinumab-aekn)ALVOFDA approval—ApprovedopenFDA Drugs@FDA
April 16, 2024WEZLANA® (ustekinumab)TEVAFDA approval—ApprovedSEC 8-K Exhibit 99.1
April 18, 2024Entyvio® (vedolizumab)TAKFDA approvalmoderately to severely active Crohn's diseaseApprovedSEC 8-K Exhibit 99.1
April 19, 2024Lumify Preservative Free (brimonidine tartrate)BLCOFDA approval—ApprovedopenFDA Drugs@FDA
April 19, 2024Zimrixby (rituximab-cdxx)RDYComplete Response Letter—CRL issuedFDA Complete Response Letters
April 19, 2024REZENOPYSCNXFDA approval—ApprovedSEC 8-K Exhibit 99.1
April 19, 2024Rezenopy (naloxone hydrochloride)SCNXFDA approval—ApprovedopenFDA Drugs@FDA
April 22, 2024ANKTIVA (inbakicept)IBRXFDA approval—Approvedsec_424b
April 24, 2024Clinolipid 20% (olive oil; soybean oil)BAXLabel expansion—ApprovedopenFDA Drugs@FDA
April 24, 2024Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
April 24, 2024Piqray (alpelisib)NVSFDA approval—ApprovedopenFDA Drugs@FDA
April 24, 2024Piqray (alpelisib)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
April 25, 2024Otezla (apremilast)AMGNLabel expansion—ApprovedopenFDA Drugs@FDA
April 26, 2024RINVOQ® (upadacitinib)ABBVFDA approval—ApprovedopenFDA Drugs@FDA
April 26, 2024RINVOQ® (upadacitinib)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
April 26, 2024AQST-108AQSTFDA approval—ApprovedSEC 8-K Exhibit 99.1
April 29, 2024Libervant® (diazepam)AQSTFDA approval—ApprovedSEC 8-K Exhibit 99.1
April 29, 2024Lupkynis (voclosporin)AUPHLabel expansion—ApprovedopenFDA Drugs@FDA
April 29, 2024Tivdak (tisotumab vedotin-tftv)PFELabel expansion—ApprovedopenFDA Drugs@FDA
April 29, 2024XOLREMDI® (mavorixafor)XFORFDA approvalCN, we expectApprovedSEC Form 10-Q
April 30, 2024Ingrezza Sprinkle (valbenazine tosylate)NBIXFDA approval—ApprovedopenFDA Drugs@FDA

April 2024: dated readouts

DateDrugCompanyEventIndicationStatusSource
Apr 2024Month disclosedDupixent (dupilumab)ABBVTopline readout—PositiveSEC Form 10-K
Apr 2024Month disclosedSimponi®ALVOTopline readoutmoderate to severe rheumatoid arthritisPositiveSEC 8-K Exhibit 99.1
Apr 2024Month disclosedAria® (golimumab)ALVOTopline readoutmoderate to severe rheumatoid arthritisPositiveSEC 8-K Exhibit 99.1
Apr 2024Month disclosedbiosimilarALVOTopline readout—PositiveSEC Form 10-K
Apr 2024Month disclosedAMX0035AMLXTopline readout—Missed primary endpointSEC Form 10-K
Apr 2024Month discloseditolizumab (EQ001)EQTopline readout—PositiveSEC Form 10-Q
Apr 2024Month disclosed—EWTXTopline readout—Positivesec_424b
Apr 2024Month disclosedSAVITRINBIXTopline readout—PositiveSEC 8-K Exhibit 99.1
Apr 2024Month disclosedosavampator (NBI-1065845)NBIXTopline readoutmajor depressive disorderPositiveSEC Form 10-K
Apr 2024Month disclosed—VXRTTopline readout—Positivesec_s1
April 15, 2024sevasemten (EDG-5506)EWTXTopline readoutBeckerPositiveSEC Form 10-Q
April 23, 2024—TOVXTopline readout—PositiveSEC Form 10-Q
April 23, 2024zabilugene almadenorepvec (VCN-01)TOVXTopline readoutrefractory retinoblastomaPositiveSEC 8-K Exhibit 99.1

April 2024: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Apr 2024Month disclosedZUSDURI (mitomycin)URGNTrial startrecurrent low-grade intermediate risk NMIBCCompletedSEC Form 10-Q
Apr 2024Month disclosedzilebesiranALNYTrial start—CompletedSEC Form 10-Q
Apr 2024Month disclosedsoquelitinib (CPI-818)CRVSTrial startmoderate to severe atopic dermatitisCompletedSEC Form 10-Q
Apr 2024Month disclosedcardiomyopathyLXEOTrial startFA cardiomyopathyCompletedSEC Form 10-Q
Apr 2024Month disclosedMNPR-101MNPRTrial start—CompletedSEC Form 10-K

2 more milestones are guided to a half-year or full-year window, or estimated from ClinicalTrials.gov primary completion dates, that overlaps April 2024. They are on each drug page and in the calendar API.

Questions

What PDUFA dates are in April 2024?

2 PDUFA dates fell in April 2024: ANKTIVA (April 23), IBRX (April 23). The FDA calendar also recorded 53 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.